NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCTID	NCT05984927 (View at clinicaltrials.gov)
Description	This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD). (Show More)
Indication	Neovascular (Wet) Age-Related Macular Degeneration
Compound Name	NG101
Sponsor	Neuracle Genetics, Inc
Funder Type	Industry
Status	Recruiting
Enrollment Count	18

Target Gene/Variant	Codon optimized aflibercept
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Genetic delivery of therapeutic protein
Route of Administration	Subretinal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV8
Editor Type
Dose 1	1 x 10^9 vg
Dose 2	3 x 10^9 vg
Dose 3	8 x 10^9 vg
Dose 4
Dose 5

No.of Trial Sites	4
Locations	Canada,United States

Has US IND	True
Recent Updates	Plans to expand trial into the USA